Trang 1 từ 29 các kết quả
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to unique formulations for treating inflammatory bowel disease (IBD), such as ulcerative colitis, including 5-amino salicylic acid (5ASA) and a phospholipid.
The present invention relates to unique compositions of
RELATED APPLICATIONS
This application claims priority to U.S. patent application Ser. No. 11/880,059, entitled "PREPARATIONS OF PHOSPHOLIPIDS AND PHARMACEUTICALS CONTAINING 5-AMINO SALICYLIC ACID FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE," filed Jul. 19, 2007 now U.S. Pat. No. 7,700,651, which
TECHNICAL FIELD
This invention relates to the production and use of therapeutic agents for the treatment of certain bowel disorders, namely disorders arising from unknown or non-obvious causes, which are unaccompanied by inflammation and are not due to detectable infection by known pathogenic
BACKGROUND OF THE PRESENT INVENTION
A great number of substances for the effective treatment of inflammatory illnesses, for example rheumatism, have been known for a long time. Since the inflammations are often chronic, the treatment with such inflammation-preventing active substances will usually
BACKGROUND OF THE PRESENT INVENTION
A great number of substances for the effective treatment of inflammatory illnesses, for example rheumatism, have been known for a long time. Since the inflammations are often chronic, the treatment with such inflammation-preventing active substances will usually
BACKGROUND OF THE PRESENT INVENTION
A great number of substances for the effective treatment of inflammatory illnesses, for example rheumatism, have been known for a long time. Since the inflammations are often chronic, the treatment with such inflammation-preventing active substances will usually
BACKGROUND OF THE PRESENT INVENTION
A great number of substances for the effective treatment of inflammatory illnesses, for example rheumatism, have been known for a long time. Since the inflammations are often chronic, the treatment with such inflammation-preventing active substances will usually
The present invention relates to a composition for oral consumption which, when taken orally can have benefits for the skin, and to the use of a combination of active compounds.
Improving the appearance and feel of human skin has received a great deal of research effort. However, the vast majority
FIELD OF THE INVENTION
The present invention relates to a group of novel pharmaceutically acceptable salts, each containing local anesthetic and anti-inflammatory activities. The preferred pharmaceutical acceptable salt in this group is diclofenac salt of lidocaine. Diclofenac is a non-steroidal
BACKGROUND OF THE INVENTION
This invention relates to the use of salicylic acid derivatives. More particularly, it relates to compositions containing salicylic acid derivatives, and the topical use thereof on animals, including man, for providing an anti-inflammatory effect.
Tissue inflammation is
BACKGROUND OF THE INVENTION
The present invention relates to compositions and processes for relieving inflammation. More specifically, vehicles comprising monoolein and a diol having 3 or 4 carbon atoms are surprisingly effective carriers for the topical administration of acetylsalicylic
BACKGROUND
Oxidative stress and inflammation are implicated in the pathogenesis of metabolic diseases, diabetes, obesity, dyslipidemia and their associated cardiovascular complications. For example, oxidative stress is a common pathogenic factor leading to insulin resistance, .beta.-cell
BACKGROUND OF THE INVENTION
A variety of skin problems including acne, scars, pigmentation disorders, sun exposure, etc., have led to the development of a variety of compositions and therapies directed toward their treatment. Such treatments may include skin creams, lotions, or ointments which are
The present invention relates to new polyprenyl compounds having excellent medicinal effects, processes for the production thereof and pharmaceutical compositions containing same.
More particularly, the present invention relates to polyprenyl compounds of the general formula: ##STR1## wherein R
FIELD OF THE DISCLOSURE
This disclosure relates to pharmaceutically active compounds obtained from natural sources. More specifically, the disclosure relates to methods of treating and preventing cancer, cardiovascular conditions, including cardiopulmonary conditions, and inflammatory responses by